Pre-MEASURE: Retrospective Analysis of the Prognostic Significance of NGS-MRD Testing in Patients With AML in First Remission Prior to Allogeneic HCT

Source: 2022 ASCO Annual Meeting*
Download Slideset
June 3-7, 2022; Chicago, Illinois
In this retrospective analysis of CIBMTR-collected blood samples, NGS-MRD detection of NPM1 mutations and/or FLT3-ITD was associated with significant prognostic value for relapse and survival in patients with AML in first remission prior to allogeneic HCT.
Format: Microsoft PowerPoint (.ppt)
File Size: 159 KB
Released: June 17, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings